Citations

Clear

112 citation(s) found for "Schaefer, PL".

Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance
Ugarte‐Gil, Manuel F. , Alarcón, Graciela S. , Seet, Andrea M. , Izadi, Zara , Montgomery, Anna , Duarte‐García, Alí , Gilbert, Emily, Valenzuela-Almada, Maria O , Wise, Leanna , Sparks, Jeffrey A. , Hsu, Tiffany , Sirotich, Emily , Hausmann, Jonathan S. , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Wallace, Zachary S. , Jacobsohn, Lindsay, Strangfeld, Anja , Mateus, Elsa F , Hyrich, Kimme L , Gossec, Laure , Lawson‐Tovey, Saskia , Kearsley‐Fleet, Lianne , Schaefer, Martin, Machado, Pedro , Schäfer, Martin , Ware, Anna , Gilbert, Emily L , Hsu, Tiffany Y-T , D'Silva, Kristin M , Patel, Naomi J , Sirotich, Emily , Liew, Jean , Hausmann, Jonathan S , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Wallace, Zachary S , Strangfeld, Anja , Mateus, Elsa F , Hyrich, Kimme L , Gossec, Laure , Carmona, Loreto , Lawson-Tovey, Saskia , Kearsley-Fleet, Lianne , Schaefer, Martin , Machado, Pedro M , Robinson, Philip C , Gianfrancesco, Milena A , Yazdany, Jinoos , Alarcón, Graciela S. , Sparks, Jeffrey A , Duarte-García, Alí , Ugarte-Gil, Manuel F , Wise, Leanna M , Liew, Jean W. , Carmona, Loreto , Robinson, Philip C. , Yazdany, Jinoos

Mayo Clinic

Arthritis Care & Research | October 14, 2022 | Volume: 75 | Issue: 1 | Pages: 53-60

10.1002/acr.25039 | PMID 36239292 Get It

ObjectiveTo determine the association between race/ethnicity and COVID‐19 outcomes in individuals with systemic lupus erythematosus (SLE).MethodsIndividuals with SLE from the US with data entered into the COVID‐19 Global Rheumatology Alliance registry between March 24, 2020 and August 27, 2021 were included. Variables included age, sex, race, and ethnicity (White, Black, Hispanic, other), comorbidities, disease activity, pandemic time period, glucocorticoid dose, antimalarials, and immunosuppressive drug use. The ordinal outcome categories were: not hospitalized, hospitalized with no oxygenation, hospitalized with any ventilation or oxygenation, and death. We constructed ordinal logistic regression models evaluating the relationship between race/ethnicity and COVID‐19 severity, adjusting for possible confounders.ResultsWe included 523 patients; 473 (90.4%) were female and the mean ± SD age was 46.6 ± 14.0 years. A total of 358 patients (74.6%) were not hospitalized; 40 patients (8.3%) were hospitalized without oxygen, 64 patients (13.3%) were hospitalized with any oxygenation, and 18 (3.8%) died. In a multivariable model, Black (odds ratio [OR] 2.73 [95% confidence interval (95% CI) 1.36–5.53]) and Hispanic (OR 2.76 [95% CI 1.34–5.69]) individuals had higher odds of more severe outcomes than White individuals.ConclusionBlack and Hispanic individuals with SLE experienced more severe COVID‐19 outcomes, which is consistent with findings in the US general population. These results likely reflect socioeconomic and health disparities and suggest that more aggressive efforts are needed to prevent and treat infection in this population.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Jatuworapruk, Kanon , Montgomery, Anna , Conway, Richard , Durcan, Laura, Graef, Elizabeth R. , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen , Cogo, Adriana Karina , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Malcata, Armando, Mateus, Elsa F , Schäfer, Martin , Scirè, Carlo Alberto , Sparks, Jeffrey A. , Strangfeld, Anja , Xavier, Ricardo Machado , Bhana, Suleman , Gore‐Massy, Monique , Hausmann, Jonathan S. , Sirotich, Emily , Sufka, Paul , Wallace, Zach, Machado, Pedro , Grainger, Rebecca , Ware, Anna , Gianfrancesco, Milena A , Conway, Richard , Durcan, Laura , Graef, Elizabeth R , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen J , Carmona, Loreto , Cogo, Adriana Karina , Duarte-García, Alí , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Langlois, Vincent , Lawson-Tovey, Saskia , Schaefer, Martin , Scirè, Carlo Alberto , Sigurdardottir, Valgerdur , Sparks, Jeffrey A , Xavier, Ricardo M , Bhana, Suleman , Hausmann, Jonathan S , Liew, Jean , Sirotich, Emily , Sufka, Paul , Wallace, Zachary S , Machado, Pedro M , Yazdany, Jinoos , Grainger, Rebecca , Robinson, Philip C , Strangfeld, Anja , Mateus, Elsa F , Carmona, Loreto , Duarte‐García, Alí , Lawson‐Tovey, Saskia , Liew, Jean W. , Yazdany, Jinoos , Robinson, Philip C.

Mayo Clinic

ACR Open Rheumatology | August 24, 2022 | Volume: 4 | Issue: 11 | Pages: 948-953

10.1002/acr2.11495 | PMID 36000538 Get It

ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
Development of cutaneous T‐cell lymphoma following exposure to biologic therapy: a Mayo Clinic retrospective analysis
Schaefer, Lauren , Comfere, Nneka I. , Sokumbi, Olayemi , Sokumbi, Olayemi

Mayo Clinic

International Journal of Dermatology | August 11, 2022 | Volume: 62 | Issue: 7 | Pages: No page available

10.1111/ijd.16386 | PMID 35950217 Get It

Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
Izadi, Zara , Aguirre, Alfredo , Hyrich, Kimme L , Gossec, Laure , Carmona, Loreto , Lawson‐Tovey, Saskia , Kearsley‐Fleet, Lianne , Schaefer, Martin, Seet, Andrea M. , Schmajuk, Gabriela , Jacobsohn, Lindsay, Rush, Stephanie, Sparks, Jeffrey A. , Hsu, Tiffany , Gilbert, Emily, Valenzuela-Almada, Maria O , Ugarte‐Gil, Manuel F. , Ribeiro, Sandra Lúcia Euzébio , Marinho, Adriana de Oliveira , Valadares, Lílian David de Azevedo , Hasseli, Rebecca , Richter, Jutta , Schmeiser, Tim , Torres, Alvaro Andres Reyes , Alle, Gelsomina , Saurit, Verónica , Zanetti, Anna , Carrara, Greta , Labreuche, Julien , Barnetche, Thomas , Hérasse, Muriel, Plassart, Samira, Santos, María José , Machado, Pedro , Sirotich, Emily , Hausmann, Jonathan S. , Sufka, Paul , Grainger, Rebecca , Bhana, Suleman , Costello, Wendy, Wallace, Zachary S. , Registry, Global Rheumatology Alliance, Schäfer, Martin , Gianfrancesco, Milena A , Aguirre, Alfredo , Lawson-Tovey, Saskia , Kearsley-Fleet, Lianne , Schaefer, Martin , Schmajuk, Gabriela , Katz, Patricia , Al-Emadi, Samar , Sparks, Jeffrey A , Wise, Leanna M , Duarte-García, Alí , Ribeiro, Sandra Lúcia Euzébio , Pfeil, Alexander , Santos, Maria José , Robinson, Philip C , Machado, Pedro M , Hausmann, Jonathan S , Grainger, Rebecca , Yazdany, Jinoos , Ugarte-Gil, Manuel F , Carmona, Loreto , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Sirotich, Emily , Hsu, Tiffany Y-T , Mateus, Elsa F , Strangfeld, Anja , Mateus, Elsa F , Katz, Patricia , Patel, Naomi J , Wise, Leanna , Duarte‐García, Alí , Di Giuseppe, Daniela , Isnardi, Carolina A , Saurit, Verónica , Khaldi-Plassart, Samira , Rodrigues, Ana Maria , Robinson, Philip C. , Liew, Jean W. , Yazdany, Jinoos , Registry, Global Rheumatology Alliance

Mayo Clinic

ACR Open Rheumatology | July 23, 2022 | Volume: 4 | Issue: 10 | Pages: 872-882

10.1002/acr2.11481 | PMID 35869686 Get It

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID‐19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID‐19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID‐19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID‐19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67‐0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%‐83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID‐19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID‐19 disease progression.
Perforated Meckel Diverticulum
Mousa, Abeer A, Mousa, Mohammad, Towbin, Richard B. , Li, Yinan , Schaefer, Carrie M. , Towbin, Alexander J.

Mayo Clinic

Applied Radiology | May 14, 2022 | Volume: No volume available | Issue: No issue available | Pages: 53-55

10.37549/ar2815 Get It

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort
Rhun, Émilie Le , Devos, Patrick , Winklhofer, Sebastian , Lmalem, Hafida, Brandsma, Dieta , Kumthekar, Priya , Castellano, Antonella , Compter, Annette , Dhermain, F., Franceschi, Enrico , Gempt, Jens , Hattingen, Elke , Hempel, Johann, Lukacova, Slávka , Minniti, Giuseppe , O’Brien, Barbara , Postma, Tjeerd J., Roth, Patrick , Schaefer, Niklaus , Thust, Steffi, Bent, Martin J. van den , Hoorn, Anouk van der , Vogin, Guillaume , Smits, Marion , Jaeckle, Kurt A. , Preusser, Matthias , Glantz, Michael , Wen, Patrick Y. , Weller, Michael , Le Rhun, Emilie , Gállego Pérez-Larraya, Jaime , Snijders, Tom J , Smits, Marion , Jaeckle, Kurt A , Preusser, Matthias , Weller, Michael , van den Bent, Martin J , Franceschi, Enrico , Roth, Patrick , Forsyth, Peter A , Furtner, Julia , Galldiks, Norbert , Rudà, Roberta , Schmidt, Nils Ole , Thust, Stefanie Catherine , Tonn, Joerg-Christian , Wen, Patrick Yung , Bendszus, Martin , Minniti, Giuseppe

Mayo Clinic

Neuro-Oncology | February 11, 2022 | Volume: 24 | Issue: 10 | Pages: 1726-1735

10.1093/neuonc/noac043 | PMID 35157772 Get It

Abstract Background Validation of the 2016 RANO MRI scorecard for leptomeningeal metastasis failed for multiple reasons. Accordingly, this joint EORTC Brain Tumor Group and RANO effort sought to prospectively validate a revised MRI scorecard for response assessment in leptomeningeal metastasis. Methods Coded paired cerebrospinal MRI of 20 patients with leptomeningeal metastases from solid cancers at baseline and follow-up after treatment and instructions for assessment were provided via the EORTC imaging platform. The Kappa coefficient was used to evaluate the interobserver pairwise agreement. Results Thirty-five raters participated, including 9 neuroradiologists, 17 neurologists, 4 radiation oncologists, 3 neurosurgeons, and 2 medical oncologists. Among single leptomeningeal metastases-related imaging findings at baseline, the best median concordance was noted for hydrocephalus (Kappa = 0.63), and the worst median concordance for spinal linear enhancing disease (Kappa = 0.46). The median concordance of raters for the overall response assessment was moderate (Kappa = 0.44). Notably, the interobserver agreement for the presence of parenchymal brain metastases at baseline was fair (Kappa = 0.29) and virtually absent for their response to treatment. 394 of 700 ratings (20 patients x 35 raters, 56%) were fully completed. In 308 of 394 fully completed ratings (78%), the overall response assessment perfectly matched the summary interpretation of the single ratings as proposed in the scorecard instructions. Conclusion This study confirms the principle utility of the new scorecard, but also indicates the need for training of MRI assessment with a dedicated reviewer panel in clinical trials. Electronic case report forms with “blocking options” may be required to enforce completeness and quality of scoring.
A fatal case of malignant atrophic papulosis in a pediatric patient
Schaefer, Lauren , Muskardin, Theresa Wampler , Tillema, Jan‐Mendelt , Wieland, Carilyn N. , Tollefson, Megha M. , Schaefer, Lauren S , Wieland, Carilyn

Mayo Clinic

Pediatric Dermatology | December 22, 2021 | Volume: 39 | Issue: 1 | Pages: 112-114

10.1111/pde.14878 | PMID 34935194 Get It

AbstractA 17‐year‐old Caucasian boy presented with progressive left‐sided weakness, transient slurred speech, and skin lesions characterized by 3‐5 mm, pink, asymptomatic papules with white atrophic centers on his central abdomen, back, and lower extremities. Skin biopsy confirmed the diagnosis of malignant atrophic papulosis, a rare vasculopathy that leads to the occlusion of small‐ and medium‐sized arteries. He was treated with cyclophosphamide, eculizumab, treprostinil, pentoxifylline, heparin, and acetylsalicylic acid. Despite the aggressive immunosuppression, humanized monoclonal antibodies, and antiplatelet therapy, he died two months after presentation. We report this case to highlight diagnostic features, as well as to highlight the importance of early diagnosis and treatment.
Comparing reliability of ICD‐10‐based COVID‐19 comorbidity data to manual chart review, a retrospective cross‐sectional study
Schaefer, Joseph , Riley, Joshua M. , Li, Michael , Cheney-Peters, Dianna , Venkataraman, Chantel M., Li, Chris J. , Smaltz, Christa, Bradley, Conor G., Lee, Crystal Y., Fitzpatrick, Danielle M., Ney, David B., Zaret, Dina, Chalikonda, Divya, Mairose, Joshua D., Chauhan, Kashyap , Szot, Margaret V., Jones, Robert B. , Bashir‐Hamidu, Rukaiya, Mitsuhashi, Shuji , Kubey, Alan , Kubey, Alan A

Mayo Clinic

Journal of Medical Virology | December 1, 2021 | Volume: 94 | Issue: 4 | Pages: 1550-1557

10.1002/jmv.27492 | PMID 34850420 Get It

AbstractInternational Statistical Classification of Disease and Related Health Problems, 10th Revision codes (ICD‐10) are used to characterize cohort comorbidities. Recent literature does not demonstrate standardized extraction methods. Objective: Compare COVID‐19 cohort manual‐chart‐review and ICD‐10‐based comorbidity data; characterize the accuracy of different methods of extracting ICD‐10‐code‐based comorbidity, including the temporal accuracy with respect to critical time points such as day of admission. Design: Retrospective cross‐sectional study. Measurements: ICD‐10‐based‐data performance characteristics relative to manual‐chart‐review. Results: Discharge billing diagnoses had a sensitivity of 0.82 (95% confidence interval [CI]: 0.79–0.85; comorbidity range: 0.35–0.96). The past medical history table had a sensitivity of 0.72 (95% CI: 0.69–0.76; range: 0.44–0.87). The active problem list had a sensitivity of 0.67 (95% CI: 0.63–0.71; range: 0.47–0.71). On day of admission, the active problem list had a sensitivity of 0.58 (95% CI: 0.54–0.63; range: 0.30–0.68)and past medical history table had a sensitivity of 0.48 (95% CI: 0.43–0.53; range: 0.30–0.56). Conclusions and Relevance: ICD‐10‐based comorbidity data performance varies depending on comorbidity, data source, and time of retrieval; there are notable opportunities for improvement. Future researchers should clearly outline comorbidity data source and validate against manual‐chart‐review.
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth
Cook, Danielle , Martin, Timothy D. , Galanko, Joseph A. , Loeza, Gabriela Herrera, Trembath, Dimitri G. , Justilien, Verline , Pickering, Karen , Jarosch, Armin , Jurmeister, Philipp , Waters, Andrew M. , Hibshman, Priya S. , Campbell, Andrew D. , Yeh, Jen Jen , Lee, Michael S. , Fields, Alan P. , Sandler, Robert S. , Sansom, Owen J. , Sers, Christine , Schaefer, Antje , Martin, Timothy D , Trembath, Dimitri G , Justilien, Verline , Pickering, Karen A , Waters, Andrew M , Lee, Michael S , Cox, Adrienne D , Sandler, Robert S , Sansom, Owen J , Sers, Christine , Schaefer, Antje , Kang, Melissa S , Loeza, Gabriela H., Vincent, David F. , Ford, Catriona A. , Keku, Temitope O , Cox, Adrienne D. , Der, Channing J

Mayo Clinic

Cancer Research | November 4, 2021 | Volume: 82 | Issue: 1 | Pages: 90-104

10.1158/0008-5472.can-20-4218 | PMID 34737214 Get It

Abstract ECT2 is an activator of RHO GTPases that is essential for cytokinesis. In addition, ECT2 was identified as an oncoprotein when expressed ectopically in NIH/3T3 fibroblasts. However, oncogenic activation of ECT2 resulted from N-terminal truncation, and such truncated ECT2 proteins have not been found in patients with cancer. In this study, we observed elevated expression of full-length ECT2 protein in preneoplastic colon adenomas, driven by increased ECT2 mRNA abundance and associated with APC tumor-suppressor loss. Elevated ECT2 levels were detected in the cytoplasm and nucleus of colorectal cancer tissue, suggesting cytoplasmic mislocalization as one mechanism of early oncogenic ECT2 activation. Importantly, elevated nuclear ECT2 correlated with poorly differentiated tumors, and a low cytoplasmic:nuclear ratio of ECT2 protein correlated with poor patient survival, suggesting that nuclear and cytoplasmic ECT2 play distinct roles in colorectal cancer. Depletion of ECT2 reduced anchorage-independent cancer cell growth and invasion independent of its function in cytokinesis, and loss of Ect2 extended survival in a KrasG12D Apc-null colon cancer mouse model. Expression of ECT2 variants with impaired nuclear localization or guanine nucleotide exchange catalytic activity failed to restore cancer cell growth or invasion, indicating that active, nuclear ECT2 is required to support tumor progression. Nuclear ECT2 promoted ribosomal DNA transcription and ribosome biogenesis in colorectal cancer. These results support a driver role for both cytoplasmic and nuclear ECT2 overexpression in colorectal cancer and emphasize the critical role of precise subcellular localization in dictating ECT2 function in neoplastic cells. Significance: ECT2 overexpression and mislocalization support its role as a driver in colon cancer that is independent from its function in normal cell cytokinesis.
Association of race/ethnicity and socioeconomic status with COVID‐19 30‐day mortality at a Philadelphia medical center using a retrospective cohort study
Cheney-Peters, Dianna , Lee, Crystal Y., Mitsuhashi, Shuji , Zaret, Dina, Riley, Joshua M. , Venkataraman, Chantel M., Schaefer, Joseph , George, Brandon , Li, Chris J. , Smaltz, Christa, Bradley, Conor G., Fitzpatrick, Danielle M., Ney, David B., Chalikonda, Divya, Mairose, Joshua D., Chauhan, Kashyap , Szot, Margaret V., Jones, Robert B. , Bashir‐Hamidu, Rukaiya, Kubey, Alan , Kubey, Alan A , Jones, Robert B.

Mayo Clinic

Journal of Medical Virology | September 29, 2021 | Volume: 94 | Issue: 3 | Pages: 906-917

10.1002/jmv.27365 | PMID 34585772 Get It

AbstractCOVID‐19 has disproportionately affected low‐income communities and people of color. Previous studies demonstrated that race/ethnicity and socioeconomic status (SES) are not independently correlated with COVID‐19 mortality. The purpose of our study is to determine the effect of race/ethnicity and SES on COVID‐19 30‐day mortality in a diverse, Philadelphian population. This is a retrospective cohort study in a single‐center tertiary care hospital in Philadelphia, PA. The study includes adult patients hospitalized with polymerase‐chain‐reaction‐confirmed COVID‐19 between March 1, 2020 and June 6, 2020. The primary outcome was a composite of COVID‐19 death or hospice discharge within 30 days of discharge. The secondary outcome was intensive care unit (ICU) admission. The study included 426 patients: 16.7% died, 3.3% were discharged to hospice, and 20.0% were admitted to the ICU. Using multivariable analysis, race/ethnicity was not associated with the primary nor secondary outcome. In Model 4, age greater than 75 (odds ratio [OR]: 11.01; 95% confidence interval [CI]: 1.96–61.97) and renal disease (OR: 2.78; 95% CI: 1.31–5.90) were associated with higher odds of the composite primary outcome. Living in a “very‐low‐income area” (OR: 0.29; 95% CI: 0.12–0.71) and body mass index (BMI) 30–35 (OR: 0.24; 95% CI: 0.08–0.69) were associated with lower odds of the primary outcome. When controlling for demographics, SES, and comorbidities, race/ethnicity was not independently associated with the composite primary outcome. Very‐low SES, as extrapolated from census‐tract‐level income data, was associated with lower odds of the composite primary outcome.